Celltrion Eyes Price Advantage For ‘Latecomer’ Bevacizumab

Planning To Leverage Biosimilar Cost Competitiveness After Filings In Korea And US

 
• By Dave Wallace
  
Vial injection syringe dollars
Celltrion is planning to leverage its cost competitiveness on bevacizumab • Source: Alamy

More from Biosimilars

More from Products